A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
← catalyst calendarNCT06549595 · readout in 1,925 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,018estimated
Sites
228
Countries
Australia, Belgium, Brazil +20
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-07 | actual | When the study began enrolling |
| Primary completion | 2031-11-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-11-26 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Untreated Follicular Lymphoma
Interventions
- Drug: Surovatamig — also filed as AZD0486
- Drug: R-CHOP
- Drug: R-CVP
- Drug: BR
Primary outcomes
what the primary-completion date above is the date OFSRI Primary: Incidence, nature and severity of AEs and SAEs. Incidence and nature of study drug discontinuations, dose reductions, and dose delays due to AEs
measured Up to 10 years
SRI Primary: Determination of the recommended Phase III dose (RP3D)
measured Up to 1 year
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
measured Up to 10 years
Phase 3 Dual Primary: To demonstrate the superiority of Surovatamig plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
measured Up to 10 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed